A-Alpha Bio launches AI antibody data consortium with GSK, Boltz and partners
read at Endpoints ↗DealPositive
A-Alpha Bio, a spin‑out founded by David Baker, announced the creation of a new consortium focused on sharing antibody design data.
The group aims to address a shortage of high‑quality data that biopharma AI engines need to improve their protein‑design models.
GSK, Boltz and several other companies have joined the effort, which will make the curated data available to AI developers for a fee.
CEO David Younger said the initiative creates a clear business opportunity while helping accelerate AI‑driven drug discovery.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “A-Alpha Bio starts AI antibody data consortium with GSK, Boltz”
read at Endpoints ↗92 words · retrieved Jul 21
comments(0)
5-min edit window · permanent after that